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Case Report
HIV Viral Rebound Due to a Possible
Drug–Drug Interaction between
Elvitegravir/Cobicistat/Emtricitabine/
Tenofovir Alafenamide and Calcium-
Containing Products: Report of 2 Cases
S. Lena Kang-Birken, PharmD1,2 , Dena El-sayed, MD1, and John Prichard, MD1
Abstract
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1
treatment and has rare emergence of drug resistance. We report a potential drug–drug interaction in 2 female patients both
receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case
involving leucovorin as calcium salt. Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and
resistance to elvitegravir and raltegravir. To the best of our knowledge, these 2 cases are the first reports of rapid emergence of
mutation from coadministration of E/C/F/TAF and calcium.
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Introduction
Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/
tenofovir alafenamide 10 mg (E/C/F/TAF) is a relatively new
antiretroviral combination having potent and durable activity
against HIV-1.1,2 It is a single tablet, once-daily (QD) regimen
containing an integrase strand transfer inhibitor, a pharmaco-
kinetic booster, and inhibitor of CYP3A, and 2 nucleoside/
nucleotide reverse transcriptase inhibitors (NNRTIs). It was
well tolerated and showed a low frequency of emerging resis-
tance during clinical trials.3,4 Drug–drug interactions have been
described including aluminum and magnesium hydroxide-
containing antacids, which decrease the absorption of
elvitegravir.5 The package insert recommends separating the
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What Do We Already Know about This Topic?
The manufacturer of elvitegravir recommends separation
of administration from aluminum, magnesium or calcium-
containing antacids without providing specific data
regarding calcium salts.
How Does Your Research Contribute to the
Field?
The cases describe new data on clinically significant drug
interaction between elvitegravir and simultaneously admi-
nistered calcium, leading to resistance-associated muta-
tions and ultimately, treatment failure.
What Are Your Research’s Implications toward
Theory, Practice, or Policy?
Clinicians should check for all forms of calcium for pos-
sible drug interaction with elvitegravir while advising the
patient to separate the administration of the 2 medications.
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administration of antacids containing aluminum, magnesium
hydroxide, or calcium carbonate from E/C/F/TAF by at least
2 hours.6 We encountered 2 cases wherein resistance to E/C/F/
TAF unexpectedly emerged during treatment of HIV-1. Both
patients were also being managed for cerebral toxoplasmosis.
We speculate that coadministered calcium may have limited
absorption of the anti-retroviral, leading to acquired resistance.
Case 1
A 42-year-old woman with no known history of HIV infection
or treatment, presented to the hospital in January 2017, follow-
ing a near syncopal episode and chronic generalized weakness.
Brain magnetic resonance imaging (MRI) showed multiple
ring-enhancing lesions in the right internal capsule and basal
ganglia with extensive vasogenic edema and a midline shift of
7 mm. She had an emergent left frontal burr hole and a place-
ment of left extraventricular drain for hydrocephalus and a
stereotactic needle biopsy of the brain confirmed cerebral tox-
oplasmosis. She was also diagnosed with HIV at this time and
her plasma HIV viral load in January 2017 was 66 500 copies/
mL and her CD4 T-cell count was 10 cells/mm3. The genotype
at this time demonstrated no reverse transcriptase (RT) gene
mutations, but the following protease gene mutations: L10V,
M36I, L63P, H69H/Y, A71T/A, and I93L. Integrase genotype
was not performed as there have been no reports of resistance to
integrase inhibitors among treatment naive individuals.
On admission in January, the patient was started on oral
sulfadiazine 1000 mg every 6 hours, pyrimethamine 75 mg
daily, and leucovorin 15 mg daily. She quickly developed pro-
found neutropenia and the regimen was changed to oral atova-
quone 1500 mg twice daily (BID) and clindamycin 600 mg
intravenous (IV) every 6 hours. The patient tolerated the new
treatment regimen, and in February 2017, E/C/F/TAF was
started. One month later in March 2017, the HIV viral load
decreased to 347 copies/mL and CD4 T-cell count increased
to 36 cell/mL.
In March 2017, the patient’s symptoms improved, and she
was discharged to a skilled nursing facility to continue the
treatment of toxoplasmosis with IV clindamycin and oral ato-
vaquone which also served as Pneumocystis jirovecii pneumo-
nia (PJP) prophylaxis, E/C/F/TAF for HIV, and fluoxetine for
depression. In April 2017, her HIV viral load further declined
to 64 copies/mL.
In May 2017, per institution’s protocol, the patient was
started on oral supplement of calcium carbonate 1500 mg
(600-mg elemental calcium) QD at the same time as E/C/F/
TAF every morning without our knowledge. In July 2017, the
HIV viral load increased to 4,840 copies/mL with the CD4 T-
cell count of 106 cells/mm3. The HIV genotype at this time
reported the RT gene mutations M184V and L100L/F, confer-
ring resistance to emtricitabine and lamivudine, and protease
gene mutations L10V, M36I/M, K43R, L63P, H69Y, A71A/V,
and I93L. Resistance to protease inhibitors was not predicted as
these were minor mutations that do not have substantial effect
on phenotype. The virus also exhibited probable resistance to
raltegravir, predicted resistance to elvitegravir, and no pre-
dicted resistance to dolutegravir. All medications were
reviewed for potential drug interactions, and good adherence
was corroborated by the staff and the medication administra-
tion record. In August 2017, the regimen was subsequently
changed to rilpivirine 25 mg/emtricitabine 200 mg/tenofovir
alafenamide 25mg (RPV/F/TAF) and darunavir 800 mg/cobi-
cistat 150 mg, and her repeat HIV viral load was <40 copies/
mL with a CD4 T-cell count of 312 cells/mm3 after 3 months
on the new regimen.
Case 2
A 35-year-old HIV-1-infected Hispanic woman with no history
of AIDS-defining opportunistic illnesses had been prescribed
efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil
fumarate 300 mg (EFV/FTC/TDF) when she established care
in December 2010. The genotype report at that time showed
protease gene mutations L63P and V77I, and the patient had
prior exposure to zidovudine, lamivudine, didanosine, and
nevirapine, since her diagnosis in 2004. Between December
2010 and January 2015, the patient experienced no medical
complications and claimed 100% compliance to EFV/FTC/
TDF during each visit which was supported by her HIV viral
load consistently <20 copies/mL over these years. In 2015, the
patient was lost to followup. Unfortunately, she discontinued
her medication in June 2016 as she was dealing with an unex-
pected death of a close family member. The patient reestab-
lished care in October 2016 at which time she was
asymptomatic with a HIV viral load of 325 000 copies/mL,
and the CD4 T-cell count was 68 cells/mm3. Atovaquone
1500 mg daily was initiated for PJP prophylaxis as the patient
reported having extensive rash with trimethoprim/sulfamethox-
azole in the past. The genotype performed at this time showed
the following protease inhibitor gene mutations: I13I/V, E35D,
D60E, L63P, I64V, and V77I and RT mutation V106I/V/M
conferring resistance to efavirenz and nevirapine. Based on
genotype and the patient’s history of exposure to multiple med-
ications, an integrase genotype was subsequently ordered in
January 2017. There was no predicted resistance to raltegravir,
elvitegravir, or dolutegravir. In the meantime, the elevated
AST and ALT of 299 IU/L and 475 IU/L prompted an ultra-
sound of the abdomen, which showed increased echogenicity
compatible with a fatty liver. With subsequent improvement of
transaminase levels, the patient was started on E/C/F/TAF in
March 2017.
One week later, she was admitted with progressively wor-
sening headache for several days with some neck stiffness but
without fever, visual disturbances or focal neurological find-
ings. The Toxoplasma antibody (immunoglobulin G) was
elevated at >5.0 IU/mL, and the brain MRI showed several
ring-enhancing lesions consistent with cerebral toxoplasmosis.
Because the patient was noted to have developed a diffuse rash
along with leukopenia in the past to sulfa-containing medica-
tions, she was initially treated with clindamycin 600 mg IV
every 6 hours and pyrimethamine 75 mg orally daily along
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with leucovorin calcium 25 mg daily. At the time of her admis-
sion, her HIV viral load had quickly declined to 2500 copies/
mL after 1 week of E/C/F/TAF without any notable adverse
reactions. However, E/C/F/TAF was temporarily suspended
upon admission to avoid further exacerbation of toxoplasmo-
sis-associated immune reconstitution inflammatory syndrome
as well as possible drug–drug interactions. Within a week of
toxoplasmosis treatment, pancytopenia was noted and leucov-
orin calcium was increased to 50 mg BID (8 mg elemental
calcium). On hospital day 10, the patient developed diffuse
morbilliform rash, fever, and transaminase elevation suspected
to be secondary to clindamycin. Clindamycin was discontinued
and the regimen was changed to atovaquone 1500 mg BID
orally and the same doses of pyrimethamine with leucovorin
calcium. The patient became afebrile and the symptoms began
to resolve within the next 24 hours.
The patient was discharged from the hospital in April 2017
with atovaquone, pyrimethamine, and leucovorin calcium only,
and E/C/F/TAF was restarted. In July 2017, her CD4 T-cell
count was 265 cells/mm3 but HIV viral load increased to 91
300 copies/mL. A repeat genotype performed at this time
showed the M184I mutation, conferring resistance to lamivu-
dine and emtricitabine, and probable resistance to raltegravir,
predicted resistance to elvitegravir but no predicted dolutegra-
vir resistance. The patient adamantly and repeatedly confirmed
100% adherence to both the antiretroviral and toxoplasmosis
regimens. She confirmed taking E/C/F/TAF with breakfast
every morning along with leucovorin calcium, atovaquone, and
pyrimethamine. She denied use of magnesium/aluminum
hydroxide or calcium carbonate antacids, vitamins, herbal sup-
plements, or any other medications that had not been pre-
scribed. She was no longer symptomatic from toxoplasmosis,
and the repeat brain MRI showed interval decrease in size of
the ring-enhancing lesions and complete resolution of vaso-
genic edema, suggesting adherence to her toxoplasmosis med-
ications and adequate absorption. In August 2017, her regimen
was changed to RPV/F/TAF and atazanavir 300 mg/cobicistat
150 mg. Based on her impressive history of allergic reactions to
sulfa-containing medications and clindamycin, any sulfa-
containing medication including darunavir was avoided. In
January 2018, the HIV viral load was <40 copies/mL and
CD4 T-cell count of 317 cells/mm3.
Discussion
Two cases are presented wherein resistance to E/C/F/TAF
emerged during treatment of an HIV infection. Both patients
had been treated for cerebral toxoplasmosis, had clinically
improved, and brain imaging demonstrated progressive resolu-
tion of lesions. All medications were reviewed in detail, and
both patients were interviewed carefully to assess their com-
pliance and administration of the medication with food. Phar-
macy refill records and the medication administration records
from the nursing facility were examined, and there were no
indications of lapses in dosing.
Virologic failure was, in both cases, unexpected. We con-
sidered several possible explanations. In our first case, resis-
tance to integrase inhibitors was not evaluated at baseline. As
such, we cannot exclude primary integrase resistance. How-
ever, we have not observed primary integrase resistance in
our clinic population, and transmitted integrase resistant
HIV-1 is extremely rare in the literature.4 Our second patient
discontinued her antiretroviral medications for a minimum of 4
months, which resulted in RT mutation V106, conferring resis-
tance to NNRTIs. Although M184V/I was not reported at this
time, it was possible that this mutation was archived. Once E/C/
F/TAF was initiated, M184V/I may have reemerged, causing
resistance to emtricitabine. This less than optimal regimen may
have led to the emergence of elvitegravir resistance mutation.
Phase 3 studies have, however, reported a 0.9% overall emer-
gence of resistance to integrase inhibitor after 144 weeks of
E/C/F/TAF.4
We speculate, however, that coadministration of calcium
may have affected absorption of the antiviral agents. In general,
serum concentrations of integrase inhibitors are decreased by
compounds that contain metal cations, such as those found in
multivitamins and antacids, if they are taken concurrently or in
a close time frame.7-9 Divalent and trivalent cations bind to
elvitegravir, forming an insoluble chelate complex and cause
decreased absorption of elvitegravir. Simultaneous administra-
tion of elvitegravir with a single dose of antacid-containing
aluminum and magnesium resulted in reduction in the serum
concentration of elvitegravir by more than 40%, in comparison
to elvitegravir alone.7 When aluminum or magnesium-
containing antacid was dosed 4 hours apart from elvitegravir,
the effect was minimal. Coadministration of calcium with elvi-
tegravir has not been studied, specifically. Similar reductions in
serum concentrations have been described with raltegravir and
1200-mg elemental calcium, as well as dolutegravir and
500-mg elemental calcium.8,9 As such, the manufacturer of
E/C/F/TAF recommends the staggered dosing of any antacid
including calcium from E/C/F/TAF.6 This recommendation
was communicated to the skilled nursing team to avoid con-
current administration in the future. The second patient only
received calcium in the form of leucovorin calcium salt. The
patient’s daily dose of leucovorin 100 mg contained approxi-
mately 8 mg of elemental calcium.10 It may be argued that such
a small amount of calcium would not result in a clinically
significant interaction. However, having reviewed other plau-
sible causes including nonadherence, malabsorption, and other
drug interactions, this possibility remains. Of note, it is esti-
mated that 50% of medications are manufactured as salt forms
to improve pharmaceutical properties as in atorvastatin calcium
and omeprazole magnesium.11
Previous studies with the integrase inhibitors raltegravir,
elvitegravir, and dolutegravir have shown significant effects
of concomitant administration with antacids. However, clinical
relevance of this interaction has not been described. To the best
of our knowledge, these 2 cases are the first reports of rapid
emergence of mutation and HIV viral rebound from coadmi-
nistration of E/C/F/TAF and calcium, possibly even at low
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doses. It may be prudent to avoid simultaneous coadministra-
tion of E/C/F/TAF with any form of calcium and to check the
salt forms of all the medications.
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